BR9914901A - Agonistas do receptor 5ht1 e metoclopramida para o tratamento de enxaqueca - Google Patents
Agonistas do receptor 5ht1 e metoclopramida para o tratamento de enxaquecaInfo
- Publication number
- BR9914901A BR9914901A BR9914901-0A BR9914901A BR9914901A BR 9914901 A BR9914901 A BR 9914901A BR 9914901 A BR9914901 A BR 9914901A BR 9914901 A BR9914901 A BR 9914901A
- Authority
- BR
- Brazil
- Prior art keywords
- metoclopramide
- migraine
- treatment
- receptor agonists
- mammal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Patente de Invenção: <B>''AGONISTAS DO RECEPTOR 5HT~ 1~ E METOCLOPRAMIDA PARA O TRATAMENTO DE ENXAQUECA''<D>. A presente invenção relaciona-se com um método de tratamento de enxaqueca em um mamífero, incluindo o ser humano, por administração ao mamífero de um agonista do receptor 5HT~ 1~, e particularmente eletriptano, em combinação com metoclopramida. Também se relaciona com composições farmacêuticas contendo um veículo farmaceuticamente aceitável, um agonista de receptor 5HT~ 1~, e metoclopramida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10632898P | 1998-10-30 | 1998-10-30 | |
PCT/IB1999/001694 WO2000025778A1 (en) | 1998-10-30 | 1999-10-18 | 5ht1 receptor agonists and metoclopramide for the treatment of migraine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9914901A true BR9914901A (pt) | 2001-07-17 |
Family
ID=22310818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9914901-0A BR9914901A (pt) | 1998-10-30 | 1999-10-18 | Agonistas do receptor 5ht1 e metoclopramida para o tratamento de enxaqueca |
Country Status (34)
Country | Link |
---|---|
US (2) | US6255334B1 (pt) |
EP (1) | EP1126840A1 (pt) |
JP (1) | JP2002528497A (pt) |
KR (1) | KR20010089363A (pt) |
CN (1) | CN1325304A (pt) |
AP (1) | AP2001002129A0 (pt) |
AR (1) | AR019246A1 (pt) |
AU (1) | AU5994799A (pt) |
BG (1) | BG105534A (pt) |
BR (1) | BR9914901A (pt) |
CA (1) | CA2348543A1 (pt) |
CO (1) | CO4950530A1 (pt) |
CZ (1) | CZ20011468A3 (pt) |
EA (1) | EA200100284A1 (pt) |
EE (1) | EE200100243A (pt) |
GT (1) | GT199900189A (pt) |
HK (1) | HK1040929A1 (pt) |
HR (1) | HRP20010298A2 (pt) |
HU (1) | HUP0104696A3 (pt) |
ID (1) | ID28291A (pt) |
IL (1) | IL141957A0 (pt) |
IS (1) | IS5898A (pt) |
MA (1) | MA26702A1 (pt) |
NO (1) | NO20012013D0 (pt) |
OA (1) | OA11669A (pt) |
PA (1) | PA8484801A1 (pt) |
PE (1) | PE20001284A1 (pt) |
PL (1) | PL347541A1 (pt) |
SK (1) | SK5522001A3 (pt) |
TN (1) | TNSN99203A1 (pt) |
TR (1) | TR200101174T2 (pt) |
TW (1) | TW524692B (pt) |
WO (1) | WO2000025778A1 (pt) |
ZA (1) | ZA200103322B (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0105131D0 (en) * | 2001-03-01 | 2001-04-18 | Pfizer Ltd | Compositions having improved bioavailability |
US6579898B2 (en) * | 2001-03-01 | 2003-06-17 | Pfizer Inc. | Compositions having improved bioavailability |
US20030051728A1 (en) | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
WO2002094218A2 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
US7498019B2 (en) | 2001-05-24 | 2009-03-03 | Alexza Pharmaceuticals, Inc. | Delivery of compounds for the treatment of headache through an inhalation route |
US6759029B2 (en) * | 2001-05-24 | 2004-07-06 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan and zolmitriptan through an inhalation route |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
US6805853B2 (en) * | 2001-11-09 | 2004-10-19 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
CA2446904A1 (en) * | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
AU2002363947A1 (en) | 2001-11-21 | 2003-07-24 | Alexza Molecular Delivery Corporation | Delivery of caffeine through an inhalation route |
EP1503744A1 (en) | 2002-05-13 | 2005-02-09 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
CA2507159A1 (en) | 2002-11-26 | 2004-06-10 | Alexza Molecular Delivery Corporation | Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain |
US7550133B2 (en) * | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
CA2526475A1 (en) | 2003-05-21 | 2004-12-02 | Alexza Pharmaceuticals, Inc. | Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
CA2569964A1 (en) * | 2004-06-10 | 2005-12-29 | Duramed Pharmaceuticals, Inc. | Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same |
US20050282879A1 (en) * | 2004-06-17 | 2005-12-22 | Foad Salehani | Methods and composition for treatment of migraine and symptoms thereof |
US7375219B2 (en) | 2005-04-13 | 2008-05-20 | Neuraxon, Inc. | Substituted indole compounds having NOS inhibitory activity |
AR060451A1 (es) * | 2006-04-13 | 2008-06-18 | Neuraxon Inc | Compuestos de indol 1,5 y 3,6-sustituidos con actividad inhibitoria de nos |
US20080139510A1 (en) * | 2006-12-07 | 2008-06-12 | Abe Rose | Treatment of migraine headaches with sublingual amino acids |
ES2594867T3 (es) | 2007-03-09 | 2016-12-23 | Alexza Pharmaceuticals, Inc. | Unidad de calentamiento para usar en un dispositivo de administración de fármaco |
CA2705422A1 (en) * | 2007-11-16 | 2009-05-22 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for treating visceral pain |
US20090131503A1 (en) * | 2007-11-16 | 2009-05-21 | Annedi Subhash C | 3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity |
EA201000808A1 (ru) * | 2007-11-16 | 2011-04-29 | Ньюраксон, Инк. | Индольные соединения и способы лечения висцеральной боли |
AU2013202680C1 (en) * | 2008-04-28 | 2016-06-23 | Zogenix, Inc. | Novel formulations for treatment of migraine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698571A (en) * | 1994-10-05 | 1997-12-16 | Eli Lilly And Company | 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine |
IL127956A0 (en) * | 1996-07-11 | 1999-11-30 | Farmarc Nederland Bv | Inclusion complex containing indole selective serotonin agonist |
GB9709739D0 (en) | 1997-05-14 | 1997-07-02 | Merck Sharp & Dohme | Pharmaceutical formulation |
-
1999
- 1999-09-01 US US09/387,990 patent/US6255334B1/en not_active Expired - Fee Related
- 1999-10-18 KR KR1020017005271A patent/KR20010089363A/ko not_active Application Discontinuation
- 1999-10-18 CA CA002348543A patent/CA2348543A1/en not_active Abandoned
- 1999-10-18 CN CN99812756A patent/CN1325304A/zh active Pending
- 1999-10-18 EA EA200100284A patent/EA200100284A1/ru unknown
- 1999-10-18 SK SK552-2001A patent/SK5522001A3/sk unknown
- 1999-10-18 WO PCT/IB1999/001694 patent/WO2000025778A1/en not_active Application Discontinuation
- 1999-10-18 HU HU0104696A patent/HUP0104696A3/hu unknown
- 1999-10-18 AP APAP/P/2001/002129A patent/AP2001002129A0/en unknown
- 1999-10-18 EE EEP200100243A patent/EE200100243A/xx unknown
- 1999-10-18 ID IDW00200100930A patent/ID28291A/id unknown
- 1999-10-18 OA OA1200100100A patent/OA11669A/en unknown
- 1999-10-18 BR BR9914901-0A patent/BR9914901A/pt not_active IP Right Cessation
- 1999-10-18 CZ CZ20011468A patent/CZ20011468A3/cs unknown
- 1999-10-18 PL PL99347541A patent/PL347541A1/xx not_active Application Discontinuation
- 1999-10-18 AU AU59947/99A patent/AU5994799A/en not_active Abandoned
- 1999-10-18 EP EP99971318A patent/EP1126840A1/en not_active Withdrawn
- 1999-10-18 JP JP2000579219A patent/JP2002528497A/ja active Pending
- 1999-10-18 IL IL14195799A patent/IL141957A0/xx unknown
- 1999-10-18 TR TR2001/01174T patent/TR200101174T2/xx unknown
- 1999-10-27 TN TNTNSN99203A patent/TNSN99203A1/fr unknown
- 1999-10-27 TW TW088118594A patent/TW524692B/zh active
- 1999-10-27 MA MA25827A patent/MA26702A1/fr unknown
- 1999-10-27 PA PA19998484801A patent/PA8484801A1/es unknown
- 1999-10-28 AR ARP990105447A patent/AR019246A1/es not_active Application Discontinuation
- 1999-10-29 GT GT199900189A patent/GT199900189A/es unknown
- 1999-10-29 PE PE1999001083A patent/PE20001284A1/es not_active Application Discontinuation
- 1999-10-29 CO CO99068659A patent/CO4950530A1/es unknown
-
2001
- 2001-03-16 IS IS5898A patent/IS5898A/is unknown
- 2001-04-19 US US09/838,440 patent/US20010020036A1/en not_active Abandoned
- 2001-04-24 ZA ZA200103322A patent/ZA200103322B/en unknown
- 2001-04-24 NO NO20012013A patent/NO20012013D0/no not_active Application Discontinuation
- 2001-04-25 HR HR20010298A patent/HRP20010298A2/hr not_active Application Discontinuation
- 2001-05-22 BG BG105534A patent/BG105534A/xx unknown
-
2002
- 2002-04-11 HK HK02102736.3A patent/HK1040929A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9914901A (pt) | Agonistas do receptor 5ht1 e metoclopramida para o tratamento de enxaqueca | |
BR0110420A (pt) | Agonistas muscarìnicos | |
BR9814923A (pt) | Método para tratamento de doença de alzheimer | |
BR0016166A (pt) | Compostos de diidropirimidina heterocìclicos | |
BR9913800A (pt) | Método para tratar glaucoma, e, composição para tratar glaucoma | |
YU2603A (sh) | Nova kombinacija (5ht2) agonista i (5ht6) antagonista serotonina kao farmaceutska kombinacija | |
BR9811780A (pt) | Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente | |
EA200101089A1 (ru) | Новый способ лечения | |
BR9908510A (pt) | Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana | |
BR0012175A (pt) | Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca | |
BR9910329A (pt) | Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto | |
BR0200246A (pt) | Tratamento de combinação para a depressão | |
EP1064966A3 (en) | Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine | |
BR0103913A (pt) | Tratamento de combinação para depressão e ansiedade | |
BR0201524A (pt) | Tratamento de combinação para ansiedade e depressão | |
BR0214497A (pt) | Composição farmacêutica que compreende um agonista do receptor 5ht1 | |
BR0201974A (pt) | Composição farmacêutica para tratamento de alterações do sono | |
BR0211855A (pt) | Medicamento e método para tratamento e melhoria da qualidade restauradora do sono | |
EP1051995A3 (en) | 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine | |
BR0005319A (pt) | Tratamento combinado para depressão e ansiedade | |
AU3600199A (en) | A pharmaceutical composition containing ezrin mutated on tyrosine 353 | |
BR9913348A (pt) | Tratamento dos distúrbios da ansiedade | |
BR0206844A (pt) | Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos | |
EP1051994A3 (en) | 5HT1 receptor agonists and a COX-2 inhibitor for the treatment of migraine | |
EP1064948A3 (en) | Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1919 DE 16/10/2007. |